| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MOUNTAIN VIEW, Calif.—RNAi-based therapeutics specialist Benitec announced it has initiated a cost-reduction plan within its U.S. subsidiary that it anticipates will let it preserve capital during a more aggressive drug development phase. Looking to save about $350,000 per month, the company has reduced its workforce by half and has introduced other cost-saving measures. The move comes as the company sought to develop its IP portfolio and drug development programs but found that it did not have sufficient cash reserves.
 
"While these cost reductions will somewhat slow our development timelines in the short-term, we have retained our core scientific team and have thus preserved the current value of our Hepatitis C and HIV drug development programs," said Sara Cunningham, Benitec CEO. "Given the tremendous excitement and investment in RNAi, from the pharmaceutical industry and through private and public equity, we will seek to capture the full value of our core assets creatively yet prudently."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A doctor wearing blue gloves and a white lab coat with a stethoscope around their neck holds a rendering of a digestive system on a glass pane with a swirled blue background.

Connecting the gut and liver to enhance drug development

Explore how a dual-organ microphysiological system connects human gut and liver tissue to bridge gaps in predicting how drugs behave in the body.
A syringe draws liquid from a glass vial, with several glass ampoules reflected on a glossy surface in the background

Turning up the heat: thermal analysis for biotherapeutics

Explore essential thermal stability techniques to ensure the safety, quality, and efficacy of biologic drugs.
A 3D-rendered image of a pink and white twisted RNA strand floating against a green, blurred cellular background.

Cutting the time and cost out of plasmid generation

Discover a hassle-free path to obtaining long, complex plasmid DNA.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue